Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ideaya Biosciences Inc (NQ: IDYA )

26.51 -0.28 (-1.05%)
Streaming Delayed Price Updated: 2:01 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 400,562
Open 27.14
Bid (Size) 26.50 (2)
Ask (Size) 26.54 (2)
Prev. Close 26.79
Today's Range 26.50 - 27.73
52wk Range 25.20 - 47.73
Shares Outstanding 48,390,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. 
Via Benzinga
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
From Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Via Business Wire

Performance

YTD
-24.73%
-24.73%
1 Month
-9.52%
-9.52%
3 Month
-33.39%
-33.39%
6 Month
-29.36%
-29.36%
1 Year
-16.29%
-16.29%

More News

Read More
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate
Via Benzinga
Unveiling 5 Analyst Insights On IDEAYA Biosciences
Via Benzinga
Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews
Via Benzinga
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 6 Experts
Via Benzinga
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q2 2024
Via InvestorPlace
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal
Via Talk Markets
MarketBeat Week in Review – 7/15 - 7/19
Via MarketBeat
Topics Economy
Exposures Interest Rates
Positive News is Driving This Cancer Drug Maker’s Stock Higher
Via MarketBeat
Recap: IDEAYA Biosciences Q4 Earnings
Via Benzinga
The Analyst Verdict: IDEAYA Biosciences In The Eyes Of 8 Experts
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
Via Benzinga
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Ideaya Biosciences Just Made Its Most Bullish Move Since March
Via Investor's Business Daily
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
IDEAYA Biosciences Inc. (NASDAQ: IDYA) is a Stock Spotlight on 1/24
Via Investor Brand Network
IDEAYA Biosciences Inc. (NASDAQ: IDYA) is a Stock Spotlight on 1/19
Via Investor Brand Network
IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q1 2024
Via InvestorPlace
Goldman Sachs Maintains Buy Rating for IDEAYA Biosciences: Here's What You Need To Know
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.